ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Ovid, Angelini Pharma Announce Agreement for OV101 americanpharmaceuticalreview
July 22, 2020Ovid Therapeutics and Angelini Pharma announced an agreement in which Angelini Pharma will be responsible to develop, manufacture and commercialize OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union, other countries..
Pharma Sources Insight July 2025
